Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Will amalgamation be a catalyst?

<< Previous

Bullboard Posts

Next >>

Comment by Layth1990on May 01, 2021 6:28pm

151 Views

Post# 33109299

RE:Will amalgamation be a catalyst?

Let us hope we don't get punched in the face because nothing is guaranteed with this management. all we can do is wait and wait for them to be productive and turn some profit for shareholders.
no one is profitable but themselves. i hope they are full by now because I really don't want to see a nasty deal that will fill their pockets with more shares.

Amalgamation can be a catalyst ? might be, depending on the deal.

I'm just hoping to be for them to be on schedule for phase 3 trial and i'm sure we will hit all time high.

<< Previous

Bullboard Posts

Next >>

2024, a breakthrough year for silver